Garcia Rodriguez, 2007102 Nested case-control Cases: 1561 | NR
UK (The Health Improvement Network database) | Upper GI perforation or bleeding | NSAID use vs. nonuse of NSAIDs (CI’s not reported and difficult to estimate from graph) Celecoxib: RR 2.7 Ibuprofen: RR 2.0 Meloxicam: RR 2.7 Diclofenac: RR 3.7 Ketoprofen: RR 5.4 Indomethacin: RR 7.2 Naproxen: RR 8.1 |
Garcia Rodriguez, 200198 Nested case-control Cases: 2105 | NR
UK (GPRD) | Upper GI perforation or bleeding | NSAID use vs. nonuse of NSAIDs Ibuprofen: RR 2.5 (95% CI 1.9 to 3.4) Etodolac: RR 2.2 (95% CI 0.4 to 11) Fenbufen: RR 1.1 (95% CI 0.2 to 5.1) Mefenamic acid: RR 2.7 (95% CI 0.8 to 9.4) Ketoprofen: RR 3.3 (95% CI 1.9 to 5.9) Nabumetone: RR 3.4 (95% CI 1.1 to 11) Tenoxicam: RR 3.4 (95% CI 0.9 to 13) Meloxicam: RR 3.8 (95% CI 0.8 to 17) Naproxen: RR 4.0 (95% CI 2.8 to 5.8) Diclofenac: RR 4.6 (95% CI 3.6 to 5.8) Flurbiprofen: RR 4.6 (95% CI 2.0 to 11) Indomethacin: RR 5.2 (95% CI 3.2 to 8.3) Piroxicam: RR 6.2 (95% CI 3.7 to 10) |
Hippisley-Cox 2005103 Nested case-control Cases: 9407 | NR; ≥ 25
UK | Complicated GI Event | NSAID use within 90 days vs. no prescription for 3 years Celecoxib: OR 1.2 (95% CI 0.91 to 1.7) Ibuprofen: OR 1.6 (95% CI 1.4 to 1.8) Diclofenac: OR 2.1 (95% CI 1.8 to 2.4) Naproxen: OR 2.0 (95% CI 1.5 to 2.6) Aspirin: OR 1.8 (95% CI 1.6 to 1.9) |
Lanas, 2006104 Case-control Cases: 2777 | NR
Spain | Hospitalization for upper G I bleeding | Celecoxib use vs. nonuse of selective NSAID: RR 1.0 (95% CI 0.4 to 2.1)
NSAID use vs. nonuse of nonselective NSAID Ibuprofen: RR 4.1 (95% CI 3.1 to 5.3) Diclofenac: RR 3.1 (95% CI 2.3 to 4.2) Aceclofenac: RR 2.6 (95% CI 1.5 to 4.6) Naproxen: RR 7.3 (95%CI 4.7 to 11) Piroxicam: RR 13 (95% CI 7.8 to −20) Indomethacin: RR 9.0 (95% CI 3.9 to 21) Meloxicam: RR 9.8 (95% CI 4.0 to 24) Ketorolac: RR 14 (95% CI 5.2 to 50) Lornoxicam: RR 7.7 (95% CI 2.4 to 24) Ketoprofen: RR 8.6 (95% CI 2.5 to 29) |
Laporte 2004105 Case-control Cases=2,813 | NR; ≥ 18
Spain and Italy | Upper GI bleeding | NSAID use vs. nonuse of NSAIDs Aspirin: OR 8.0 (95% CI 6.7 to 9.6) Dexketoprofen: OR 4.9 (95% CI 1.7 to 14) Diclofenac: OR 3.7 (95% CI 2.6 to 5.4) Ibuprofen: OR 3.1 (95% CI 2.0 to 4.9) Indomethacin: OR 10 (95% CI 4.4 to 23) Ketoprofen: OR 10 (95% CI 3.9 to 26) Ketorolac: OR 25 (95% CI 8.0 to 77) Meloxicam: OR 5.7 (95% CI 2.2 to 15) Naproxen: OR 10 (95% CI 5.7 to 18) Nimesulide: OR 3.2 (95% CI 1.9 to 5.6) Piroxicam: OR 16 (95% CI 10 to 24) |
Mamdani 2002106 Cohort n=143,969 | 75.7
Canada | Upper GI hemorrhage | NSAID use vs. no use of NSAIDs Celecoxib: HR 1.0 (95% CI 0.7 to 1.6) Diclofenac + misoprostol: HR 3.0 (95% CI 1.7 to 5.5) Nonselective NSAIDs: HR 4.0 (95% CI 2.3 to 6.9)
NSAID use vs. celecoxib Diclofenac + misoprostol: HR 3.2 (95% CI 1.6 to 6.5) Nonselective NSAIDs: HR 4.4 (95% CI 2.3 to 8.5) |
Mellemkjaer, 2002107 Cohort n=156,138 NSAID users | NR
Denmark | Hospitalization for GI bleeding | NSAID use vs. no use of NSAIDs Diclofenac: RR 4.9 (95% CI 3.5 to 6.6) Ibuprofen: RR 2.4 (95% CI 2.0 to 2.9) Indomethacin: RR 4.3 (95% CI 2.9 to 6.0) Ketoprofen: RR 6.3 (95% CI 4.5 to 8.5) Naproxen: RR 3.0 (95% CI 2.1 to 4.2) Piroxicam: RR 5.0 (95% CI 3.3 to 7.2) |
Rahme, 2007108 Retrospective cohort N=510,871 | NR; ≥65
Canada | Hospitalization for GI bleeding | NSAID use vs. acetaminophen use Celecoxib: HR 0.82 (95% CI 0.66 to 1.0) Ibuprofen: HR 1.1 (95% CI 0.56 to 2.2) Diclofenac: HR 1.2 (95% CI 0.86 to 1.6) Naproxen: HR 2.8 (95% CI 2.0 to 3.7) |